Coastlands Holds 5.34% Of ALX Oncology Through Its Investment Partnership
The passive position covers 6,906,783 shares as the cancer-drug developer prepares for an expected December trial update.
Coastlands Capital, an investment adviser, reported Thursday a 5.34% passive stake in ALX Oncology, which develops cancer therapies, in an SEC ownership disclosure. The position covers 6,906,783 common shares held directly by Coastlands Capital Partners as of November 12.
The Partnership Holds The Shares
Coastlands Capital Partners holds the stock for its investors and can receive or direct dividends and proceeds from share sales. Coastlands Capital serves as the partnership's investment adviser.
Matthew D. Perry, the control person of the Coastlands entities, reported shared voting authority over the same shares. The partnership, its adviser, the related Coastlands entities and Perry each reported the same position; those entries describe the shares held by the partnership.
The reported percentage uses 129,274,568 common shares outstanding as of November 9. Coastlands certified that the securities were bought and are held without an aim or effect of influencing ALX's control.
Cancer Trials And $147.2 Million
ALX reported $147.2 million in cash, cash equivalents and investments at September 30. Management expects those resources to fund planned operations through the first half of 2028.
The company has no approved products for sale. Its candidates include evorpacept, which blocks CD47—a protein that helps cancer cells evade immune attacks—and ALX2004, an antibody-drug conjugate targeting EGFR, a protein on some tumors.
Evorpacept's development includes a mid-stage study in metastatic HER2-positive breast cancer. In September, ALX announced published gastric-cancer trial findings showing higher response rates than the control treatment, supporting further development of the drug.
Jazz Pharmaceuticals and Sanofi sponsor studies pairing evorpacept with their own medicines. ALX's annual-report profile said approximately 800 subjects had received evorpacept alongside other cancer treatments.
ALX2004's December Readout
ALX2004 entered an early-stage trial in August 2025. ALX expects safety and early efficacy findings in December 2026 from that study in patients with selected advanced or metastatic solid tumors.
Sources
- SCHEDULE 13G — Coastlands Capital LP re: ALX Oncology Holdings Inc. (ALXO) — SEC EDGAR
- SCHEDULE 13G Exhibit 99.1 — EXHIBIT 99.1 — SEC EDGAR
- ALX Oncology Reports Third Quarter 2026 Financial Results — globenewswire.com